{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:41:03Z","timestamp":1763142063447,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010067","name":"Government of Arag\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010067","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.atherosclerosis.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T21:25:26Z","timestamp":1684272326000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals"],"prefix":"10.1016","volume":"375","author":[{"given":"Diego","family":"Casas-Deza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Espina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mart\u00ednez-Sapi\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"del Moral-Bergos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pilar","family":"Garcia-Sobreviela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Lopez-Yus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Calmarza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Bernal-Monterde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-3737","authenticated-orcid":false,"given":"Jose M.","family":"Arbones-Mainar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012143.pub3","article-title":"Direct\u2010acting antivirals for chronic hepatitis C","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib4","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3748\/wjg.v22.i4.1461","article-title":"Metabolic alterations and hepatitis C: from bench to bedside","volume":"22","author":"Chang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib5","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of low- and very-low-density hepatitis C virus RNA-containing particles","volume":"76","author":"Andr\u00e9","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00198849","article-title":"Association of hepatitis C virus in human sera with \u03b2-lipoprotein","volume":"181","author":"Thomssen","year":"1992","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00422-17","article-title":"Hepatitis C virus strain-dependent usage of apolipoprotein E modulates assembly efficiency and specific infectivity of secreted virions","author":"Weller","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.23278","article-title":"Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles","volume":"51","author":"Benga","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib9","doi-asserted-by":"crossref","first-page":"12680","DOI":"10.1128\/JVI.01476-09","article-title":"Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles","volume":"83","author":"Jiang","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib10","first-page":"436","article-title":"Serum cholesterol and chronic hepatitis C","volume":"28","author":"Maggi","year":"1996","journal-title":"Ital. J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1572-0241.2003.07402.x","article-title":"Hepatitis C virus\u2013associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis","volume":"98","author":"Petit","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.510290235","article-title":"Association of diabetes mellitus and chronic hepatitis C virus infection","volume":"29","author":"Mason","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clinre.2016.09.008","article-title":"Hepatitis C virus and atherosclerosis: a legacy after virologic cure?","volume":"41","author":"Bassendine","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.puhe.2016.04.005","article-title":"Hepatitis C and risk of coronary atherosclerosis - a systematic review","volume":"138","author":"Olubamwo","year":"2016","journal-title":"Publ. Health"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/diacare.19.4.390","article-title":"Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state","volume":"19","author":"Lewis","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib16","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/ATVBAHA.111.241463","article-title":"Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia","volume":"32","author":"Sparks","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib17","article-title":"Interdependence of glycemic and lipid modulation in cured chronic hepatitis C patients by direct-acting antiviral agents","author":"Cheng","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib18","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.3390\/jcm11144049","article-title":"Evaluation of cardiovascular risk factors after hepatitis C virus eradication with direct-acting antivirals in a cohort of treatment-na\u00efve patients without history of cardiovascular disease","volume":"11","author":"Casas-Deza","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1194\/jlr.D050120","article-title":"Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered (1)H NMR spectroscopy","volume":"56","author":"Mallol","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.27424","article-title":"Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1\u2013infected patients","volume":"61","author":"Meissner","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAD.0000000000000026","article-title":"HIV\/HCV coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection","volume":"28","author":"Wheeler","year":"2014","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.gastrohep.2018.07.010","article-title":"Guidelines on treatment of hepatitis C virus infection. Spanish association for the study of the liver (AEEH)","volume":"41","author":"Calleja","year":"2018","journal-title":"Gastroenterol. Hepatol. Engl. Ed."},{"year":"2019","series-title":"Global Status Report on Alcohol and Health 2018","author":"World Health Organization","key":"10.1016\/j.atherosclerosis.2023.05.003_bib23"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C","volume":"20","author":"Bedossa","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib26","first-page":"1","article-title":"Apolipoprotein E polymorphism and atherosclerosis, Arterioscler","volume":"8","author":"Davignon","year":"1988","journal-title":"Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12967-019-2033-x","article-title":"Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study","volume":"17","author":"Rinaldi","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers12061351","article-title":"Risk of hepatocellular carcinoma after HCV clearance by direct-acting antivirals treatment predictive factors and role of epigenetics","volume":"12","author":"Rinaldi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2018.11.022","article-title":"Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events","volume":"156","author":"Butt","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2020.01.010","article-title":"Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: a prospective multicentre study","volume":"296","author":"Adinolfi","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib32","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.2337\/dc06-0456","article-title":"Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection","volume":"29","author":"Sim\u00f3","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib33","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct\u2010acting antiviral agents","volume":"90","author":"Ciancio","year":"2018","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib35","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/dom.14168","article-title":"Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib36","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3390\/cells10112934","article-title":"Decoupled glucose and lipid metabolic recovery after viral clearance in direct-acting antiviral-treated HCV patients: a 3-year prospective cohort study","volume":"10","author":"Lee","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib37","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.numecd.2021.04.016","article-title":"Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes","volume":"31","author":"Sasso","year":"2021","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"year":"2017","series-title":"Effect of Antiviral Therapy for HCV on Lipid Levels","author":"Mauss","key":"10.1016\/j.atherosclerosis.2023.05.003_bib38"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2012.03.060","article-title":"High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic study of atherosclerosis)","volume":"60","author":"Mackey","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCULATIONAHA.113.002671","article-title":"High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy","volume":"128","author":"Mora","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib41","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.3390\/ijms20133151","article-title":"HDL triglycerides: a new marker of metabolic and cardiovascular risk","volume":"20","author":"Girona","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2017.01.001","article-title":"RISC Investigators, Plasma HDL-cholesterol and triglycerides, but not LDL-cholesterol, are associated with insulin secretion in non-diabetic subjects","volume":"69","author":"Natali","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.dsx.2018.10.006","article-title":"Metabolic Syndrome Research Group, High triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight healthy adults","volume":"13","author":"Pantoja-Torres","year":"2019","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-021-01348-w","article-title":"Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study","volume":"20","author":"Sokooti","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/diabetes.51.1.7","article-title":"Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes","volume":"51","author":"McGarry","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib46","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.2337\/db07-0056","article-title":"Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic \u03b2-cell dysfunction","volume":"56","author":"Hao","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2023.05.003_bib47","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1194\/jlr.M800238-JLR200","article-title":"Cholesterol accumulation and diabetes in pancreatic \u03b2-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity","volume":"49","author":"Ishikawa","year":"2008","journal-title":"J. Lipid Res."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023001867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023001867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:27:13Z","timestamp":1762187233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":47,"alternative-id":["S0021915023001867"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.05.003","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}